How Prolonged Fasting Reshapes Your Hormones and What It Means for Longevity

Prolonged fasting—defined by international consensus as four or more consecutive days of near-complete caloric abstinence—activates a qualitatively distinct endocrine program that short-term or intermittent fasting protocols do not fully replicate. This 2025 narrative review by Herman and colleagues at the University of Ljubljana synthesizes available preclinical and human evidence on axis-by-axis hormonal adaptations during prolonged fasting, evaluating both the potential healthspan benefits and the clinical risks.

Across the hypothalamic–pituitary–somatotropic (HPS) axis, the most striking finding is a paradoxical dissociation: within 3–5 days, circulating IGF-1 falls by up to 65% while GH secretion rises due to loss of negative feedback. Lower IGF-1 activity has been linked to longevity in multiple animal models and in human centenarian cohorts, and reduced IGF-1 suppresses the PI3K–Akt–mTOR pathway, potentially lowering cancer risk and promoting autophagy. On the thyroid axis, fasting induces a functional 'low T3 syndrome'—falling triiodothyronine with relatively preserved TSH—interpreted as an energy-conservation adaptation rather than true hypothyroidism. The HPA axis responds with transient hypercortisolemia that mobilizes fuel but may become maladaptive if prolonged. The hypothalamic–pituitary–gonadal axis is suppressed, with falling LH pulsatility and sex steroids, raising concerns about reproductive health in extended or repeated fasting cycles. The renin–angiotensin–aldosterone system activates in response to volume contraction, risking electrolyte disturbances. Adipokine networks shift favorably—leptin drops, ghrelin rises transiently, and adiponectin may increase—collectively signaling improved insulin sensitivity and reduced inflammatory tone.

The metabolic switch from glucose to fatty acids and ketones, occurring within 12–36 hours and deepening thereafter, is central to these endocrine changes. Ketone bodies act not merely as fuel but as signaling molecules that promote autophagy, sirtuin activation, and cellular stress resistance—mechanisms with plausible relevance to aging and chronic disease prevention. Human cohort data from medically supervised 4–21-day fasting programs confirm physiological tolerability in selected individuals, with signals for cardiometabolic improvement.

Despite this mechanistic plausibility, the authors emphasize that the evidence base is seriously limited. Most human studies are small, short, methodologically heterogeneous, and rely on surrogate endpoints. Endocrine outcomes are frequently secondary and inconsistently reported. Critical confounders—sex, age, menstrual-cycle phase, adiposity, and baseline metabolic health—are rarely controlled. Single time-point hormone measurements miss pulsatility dynamics, and few studies include deep endocrine phenotyping or refeeding characterization.

The clinical risks are non-trivial: transient hypogonadism, relative hypothyroidism, hypercortisolemia, orthostatic intolerance, lean mass catabolism, and refeeding syndrome all require monitoring. The authors argue that adaptive endocrine responses must be carefully distinguished from maladaptive consequences that emerge when fasting is prolonged, repeated, or applied to vulnerable individuals without supervision. They call for harmonized fasting protocols, sex- and phenotype-stratified designs, longitudinal endocrine phenotyping, and randomized trials with hard clinical endpoints before prolonged fasting can be recommended as a broadly applicable therapeutic or longevity intervention.